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Abstract 
 
Purpose: The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 is the standard for 
oncology toxicity encoding and grading despite limited validation. We assessed inter-rater reliability 
(IRR) in multi-reviewer toxicity identification. 
Methods and Materials: Two reviewers independently reviewed 100 randomly selected notes for weekly 
on-treatment visits during radiotherapy from the electronic health record (EHR). Discrepancies were 
adjudicated by a third reviewer for consensus. Term harmonization was performed to account for 
overlapping symptoms in CTCAE. IRR was assessed based on unweighted and weighted Cohen’s kappa 
coefficients. 
Results: Between reviewers, unweighted kappa was 0.68 (95% CI 0.65-0.71) and weighted kappa 0.59 
(0.22-1.00). IRR was consistent between noted present or absent symptoms with kappa of 0.6 (0.66-0.71) 
and 0.6 (0.65-0.69), respectively.  
Conclusions: Significant discordance suggests toxicity identification, particularly retrospectively, is a 
complex and error prone task. Strategies to minimize IRR, including training and simplification of the 
CTCAE criteria, should be considered in trial design and future terminologies.  
Introduction 
The NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0 is the current standard for 
oncology toxicity encoding and grading, though reliability studies and validation have been limited.1 
Inter-rater reliability (IRR) impacts both prospective and retrospective studies, given reliance on multiple 
individuals to assess toxicities. Prior data suggest variability between clinicians and research assistants in 
grading toxicities2,3 and underreporting in clinical trials versus retrospective chart review.4 Thus, 
retrospective chart review has been considered the gold standard and review by clinical research assistants 
is frequently employed to capture acute events. The increasing complexity of CTCAE across versions has 
also made acute event grading more challenging.3 Variability of toxicity identification, necessary for 
accurate grading, has not been quantified; this may further reveal shortcomings of both toxicity 
identification and, more broadly, retrospective studies to guide future improvement. 
 
Methods and Materials 
This study was approved by the Duke University Medical Center Institutional Review Board 
(Pro00082776). Two senior radiation oncology residents independently reviewed 100 randomly selected 
notes for weekly on-treatment visits (OTVs) from the electronic health record (EHR) from 2005-2016. 
Patients undergoing radiotherapy have weekly visits to assess and manage potential acute toxicities of 
treatment. These notes can be institution-specific but typically include a brief subjective section 
describing patient symptoms, an objective section detailing a limited and focused physical exam, and a 
brief assessment and plan. At our institution, OTV notes are documented in the broader medical center 
EHR and free text comprises the majority of notes, although vital signs and physical exam headers are 
prepopulated and physical exam findings can be selected from predefined options. Style and content 
varied across physicians and disease site. At other institutions, OTVs may be documented using more 
structured formats with limited free text. OTV notes were selected given their overall simplicity in 
comparison to consultation or follow-up notes which tend to have significant text generated from the 
EHR. CTCAE v5.0 symptoms were identified as explicitly present, absent, or not mentioned. Reviewers 
were instructed to identify all mentioned symptoms and were blinded to each other’s identifications. An 
attending radiation oncologist acted as a tie-breaker and evaluated disagreements to facilitate an overall 
consensus. We created a thesaurus to harmonize overlapping CTCAE terms (Supplementary Material). 
IRR was assessed based on unweighted and weighted Cohen’s kappa coefficients between reviewers and 
versus the consensus.5,6 The Kappa coefficient is a commonly used measure of IRR which accounts for 
agreement due to chance, and ranges from -1 to +1, where 0 is agreement expected from random chance 
and 1 is perfect agreement.7 The weighted Cohen’s kappa coefficient was calculated with greater weight 
given to symptoms where one reviewer designated a symptom as explicitly present, while the other 
identified it as explicitly absent. We additionally evaluated IRR separately for explicitly present and 
absent symptoms. 
 
Results 
One hundred notes written by 15 physicians and representing many disease sites revealed disagreements 
in symptom identification in 93 notes, with median 4 per note (range 1-12) (Table 1). Figure 1 illustrates 
relationships between reviewers and the consensus with regard to present and absent symptoms. Radiation 
dermatitis and pain were among the most common documented symptoms. Certain terms were more 
thoroughly captured by individual reviewers, including non-infectious cystitis, folliculitis, and soft tissue 
fibrosis. 
 
Between the blinded raters, inter-rater unweighted kappa was 0.59 (95% CI 0.56-0.62) and weighted 
kappa was 0.5 (-1.00-1.00). With harmonization, this improved, with unweighted kappa 0.68 (95% CI 
0.65-0.71) and weighted kappa 0.59 (0.22-1.00). Consensus agreement with each reviewer was 
asymmetric, with unweighted kappa of 0.95 (0.93-0.96) and 0.75 (0.72-0.77), and weighted kappa of 0.93 
(0.93-0.93) and 0.67 (CI 0.67-0.67). IRR was consistent between noted present or absent symptoms with 
kappa of 0.6 (0.66-0.71) and 0.6 (0.65-0.69), respectively. 
 
Discussion 
CTCAE remains the cornerstone of standardized oncology toxicity grading, with retrospective chart 
review playing an important role in acute toxicity identification. Nevertheless, significant discordance 
was present even with two practicing resident physicians (familiar with CTCAE and responsible for 
routine documentation) reviewing brief clinical notes with limited automatically populated content such 
as past medical history or social history from the EHR. This suggests that consistent identification, 
upstream of toxicity grading, is a challenging.2,3 Moreover, variability may even be underestimated in this 
study as only 77 of 808 possible harmonized terms were present by consensus. This study demonstrates 
the limitations of retrospective toxicity review, despite its use as a gold standard in prior work and 
auditing due to underreporting in prospective studies.4 Our findings also highlight general shortcomings 
of retrospective studies. As manual review can be laborious, many studies rely on chart abstraction from 
single reviewers and some have multiple reviewers abstracting data from different patients. Our findings 
emphasize the caution that is required in interpreting this abstracted data. 
 
Multiple plausible factors contribute to discordance. In particular, the CTCAE has increased in 
complexity,3 including 837 terms across 26 categories in v5.0, increased from 49 and 9, respectively, in 
v1.0. Perhaps not surprisingly, selecting the appropriate term can be problematic; rectal bleeding from 
prostate cancer radiotherapy may be coded in accurate terms such as “proctitis” or “rectal hemorrhage.” 
We developed and have made available a harmonization thesaurus to account for common symptoms 
encountered in this study with overlapping terms such as hematochezia and pain. The improvement in 
kappa with harmonization reinforces the potential redundancy of CTCAE terms and demonstrates, to a 
degree, how this impacts inter-rater variability. These results support a prior study which demonstrated 
that the increase in terms from CTCAE v1.0 to v4.0 resulted in a decreasing ability for clinical research 
assistants to conclusively grade acute events.3 
 
This complexity may also limit the number of symptoms a human reviewer can actively recall during 
identification, reflected by the discrepancy in the identification of specific symptoms, such as non-
infectious cystitis, folliculitis, and soft tissue fibrosis. Some inter-rater variability in our study may also 
stem from elements of ambiguity in clinical documentation, including those due to uncertain terms or 
chronological changes. CTCAE does not account for symptom changes over time;5 thus a statement such 
as “sore throat earlier in the week that resolved” could be coded as both present and absent. Other terms 
such as “minimal” can also contribute to human variability. 
 
Contributions of retrospective review to IRR are also important to consider in this study, given variability 
in documentation style and author identification. Additionally, our practice at our institution has been to 
rely heavily on unstructured free text OTV notes. Greater structure for reporting toxicities such as drop-
down menus may improve future extraction, though the high complexity of CTCAE may make 
comprehensive collection difficult. However, while some retrospective series are based prospectively 
structured collected outcomes, this has been documented to result in greater underreporting than those 
based on retrospective review.4 While our study focused on identifying toxicities described in OTV notes, 
larger studies often abstract data from even more complex consult and follow-up notes, which likely 
increase the cognitive burden on the reviewer and may result in even greater variability. 
 
Finally, variations in the “completeness” of reviewer assessment, particularly with negated symptoms, 
impact the overall IRR. Explicitly positive symptoms or unambiguous categorical items, such as 
laboratory data, are abstracted with high fidelity.1,4 More variability, though, occurs when inference is 
required, particularly in identifying explicitly negative symptoms; “OP/OC clear” during head and neck 
treatment plausibly relates to the absence of thrush and/or mucositis; “dysphagia is improved” is 
ambiguous regarding resolution versus a continued, albeit less severe, presence. Despite these challenges 
of CTCAE, though, there did not appear to be greater variability with explicitly present or absent 
symptom identification. 
 
Our study has limitations, particularly small sample size and number of reviewers given the intensiveness 
of manual review of the expansive CTCAE terminology. While this does limit our ability to quantify the 
degree of IRR, it does reflect common research practice in both retrospective and prospective settings, 
where the burden of manual review frequently limits studies to one reviewer. Metrics for interrater 
reliability each have limitations, and the Kappa metric assumption of independence may underestimate 
agreement.7 However, Kappa has the advantage of accounting for potential concordance due to chance, 
particularly important given that, as in many studies, much of the CTCAE terminology was not used. 
Prior experience in EHR data extraction in general nor CTCAE toxicity identification was not 
standardized amongst the reviewers, though neither reviewer had additional experience abstracting 
toxicities beyond clinical training of a senior resident. Reviewers were asked to identify all potential 
toxicities and did not receive dedicated CTCAE harmonization or delineated rules for ambiguous terms. 
Restricting the CTCAE or standardization efforts may improve IRR.8 However, this reflects common 
practice and emphasizes that training may be an appropriate strategy in studies, particularly in multi-
institutional and cooperative group settings.  
 
Finally, the growing experience around patient-reported outcomes9 and interest in EHR extraction with 
natural language processing10 may offer complementary sources of data to augment the accurate 
identification of acute events. 
 
Despite these limitations, this study demonstrates the discrepant nature of toxicity identification with a 
diverse set of notes in a setting which should optimize IRR. 
 
Conclusions 
In conclusion, retrospective clinician CTCAE symptom identification and, more broadly, retrospective 
chart review, are variable and can impact clinical study reporting, generalizability, and intra-study 
comparison. Standardization efforts and simplification should be considered in study design and future 
coding terminologies, respectively. 
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 Figure 1. Interrater variability of note-terms with harmonization of terms 
With harmonization based on a thesaurus defining synonymous terms, there remained high rates of discordance 
between reviewers identifying explicitly present (A) and absent (B) symptoms in on-treatment visit notes. Overall 
weighted kappa coefficient was weighted kappa 0.59 (0.22-1.00). Variability was identified in both noted present 
and absent symptoms with kappa of 0.6 (0.66-0.71) and 0.6 (0.65-0.69), respectively. 
  
Table 1. Note characteristics and extracted symptoms 
Word Count Median 203 IQR 164.5-237.5  
Character Count Median 1324.5  IQR 1103.25-1592.5  
Number of note authors 15   
Disease Site Number (N=100)   
Breast 32   
Head and Neck 15   
Prostate 13   
Central Nervous System 10   
Lung 8   
Gynecologic 7   
Bladder 4   
Metastases (spine, spine, adrenal, 
leg/lung) 
4   
Sarcoma 3   
Esophagus 1   
Skin 1   
Pelvic Lymphoma 1   
Multiple Myeloma 1   
Most common present 
symptoms 
Number Present (Consensus) 
(N=100) 
Reviewers agree 
present 
Reviewer 
discordance 
Dermatitis-Radiation 35 21 15 
Fatigue 34 15 20 
Pain 24 15 10 
Nausea 13 9 4 
Pruritus 11 7 4 
Cystitis, noninfectious 9 0 9 
Diarrhea 8 7 1 
Urinary Urgency 8 5 2 
Mucositis 8 7 3 
Folliculitis 7 0 7 
Hot Flashes 7 5 2 
Total 277 149 156 
    
Most common absent 
symptoms 
Number Absent (Consensus) 
(N=100) 
Reviewers agree 
absent 
Reviewer 
discordance 
Dermatitis-Radiation 42 27 23 
Pain 27 18 14 
Superficial Soft Tissue Fibrosis 19 0 19 
Diarrhea 18 16 2 
Seroma 18 16 2 
Thrush 16 1 15 
Hematochezia 16 15 2 
Hematuria 16 13 3 
Dysuria 15 12 4 
Pruritis 13 6 8 
Urinary incontinence 13 12 1 
Total 358 193 211 
IQR: Interquartile range 
*Number present or absent based on consensus adjudication of identifications by both reviewers, rather than the 
total number of times symptoms were identified by either reviewer. 
 
